tiprankstipranks
Advertisement
Advertisement

HK:1672 Stock Latest News

Ascletis Showcases Differentiated Oral Obesity Drugs at ADA 2026
Company AnnouncementsAscletis Showcases Differentiated Oral Obesity Drugs at ADA 2026
9d ago
1672
Ascletis Pharma Sets 2026 AGM and Seeks Renewal of Share Issuance Mandate
PremiumCompany Announcements
Ascletis Pharma Sets 2026 AGM and Seeks Renewal of Share Issuance Mandate
11d ago
1672
Ascletis Pharma Seeks Shareholder Approval to Modernize Governance Rules
PremiumCompany Announcements
Ascletis Pharma Seeks Shareholder Approval to Modernize Governance Rules
14d ago
1672
Ascletis to Showcase Promising Obesity Drug Pipeline at ECO 2026
PremiumCompany Announcements
Ascletis to Showcase Promising Obesity Drug Pipeline at ECO 2026
1M ago
1672
Ascletis to Unveil Obesity and Metabolic Drug Data at ADA 2026
PremiumCompany Announcements
Ascletis to Unveil Obesity and Metabolic Drug Data at ADA 2026
2M ago
1672
Ascletis Completes U.S. Phase II Enrollment for Oral GLP-1 Diabetes Drug ASC30
PremiumCompany AnnouncementsAscletis Completes U.S. Phase II Enrollment for Oral GLP-1 Diabetes Drug ASC30
2M ago
1672
Ascletis Advances Fixed-Dose Oral Obesity Pill Toward U.S. FDA IND in 2026
Premium
Company Announcements
Ascletis Advances Fixed-Dose Oral Obesity Pill Toward U.S. FDA IND in 2026
2M ago
1672
Ascletis Deepens R&D Push in Obesity Drugs as 2025 Loss Widens
Premium
Company Announcements
Ascletis Deepens R&D Push in Obesity Drugs as 2025 Loss Widens
3M ago
1672
Ascletis Pharma Sets March 31 Board Meeting to Approve 2025 Results and Consider Dividend
PremiumCompany Announcements
Ascletis Pharma Sets March 31 Board Meeting to Approve 2025 Results and Consider Dividend
3M ago
1672
Ascletis Advances Oral Amylin Agonist ASC39 Toward U.S. IND for Obesity
PremiumCompany Announcements
Ascletis Advances Oral Amylin Agonist ASC39 Toward U.S. IND for Obesity
3M ago
1672
Ascletis Posts Positive U.S. Phase II Data for Monthly GLP-1 Obesity Drug ASC30
PremiumCompany Announcements
Ascletis Posts Positive U.S. Phase II Data for Monthly GLP-1 Obesity Drug ASC30
3M ago
1672
Ascletis Advances Oral Amylin Obesity Drug ASC36 Toward U.S. Clinical Trials
PremiumCompany Announcements
Ascletis Advances Oral Amylin Obesity Drug ASC36 Toward U.S. Clinical Trials
4M ago
1672
Ascletis Raises HK$835 Million to Fund Global Phase III Obesity Drug Trials
PremiumCompany AnnouncementsAscletis Raises HK$835 Million to Fund Global Phase III Obesity Drug Trials
4M ago
1672
Ascletis Pharma to Raise HK$835 Million via Share Placement to Fund Obesity Drug Trials
Premium
Company Announcements
Ascletis Pharma to Raise HK$835 Million via Share Placement to Fund Obesity Drug Trials
4M ago
1672
Ascletis Reports Positive Long-Term Phase III Safety Data for First-in-Class Oral Acne Drug Denifanstat
Premium
Company Announcements
Ascletis Reports Positive Long-Term Phase III Safety Data for First-in-Class Oral Acne Drug Denifanstat
5M ago
1672
Ascletis Starts U.S. Phase II Diabetes Trial of Oral GLP-1 Drug ASC30 After Strong Obesity Data
PremiumCompany Announcements
Ascletis Starts U.S. Phase II Diabetes Trial of Oral GLP-1 Drug ASC30 After Strong Obesity Data
5M ago
1672
Ascletis Advances Next-Generation Once-Monthly Triple Agonist ASC37 for Obesity Into Clinical Pathway
PremiumCompany Announcements
Ascletis Advances Next-Generation Once-Monthly Triple Agonist ASC37 for Obesity Into Clinical Pathway
5M ago
1672
Ascletis Wins FDA Green Light for Phase II U.S. Diabetes Trial of Oral GLP-1 Drug ASC30
PremiumCompany Announcements
Ascletis Wins FDA Green Light for Phase II U.S. Diabetes Trial of Oral GLP-1 Drug ASC30
5M ago
1672
Ascletis Pharma Upsizes Share Repurchase to HK$500 Million Amid Drug Development Success
PremiumCompany Announcements
Ascletis Pharma Upsizes Share Repurchase to HK$500 Million Amid Drug Development Success
6M ago
1672
Ascletis Pharma Reports Positive Phase I Results for ASC50
PremiumCompany AnnouncementsAscletis Pharma Reports Positive Phase I Results for ASC50
6M ago
1672
Ascletis Pharma’s Acne Treatment Drug Application Accepted by China NMPA
Premium
Company Announcements
Ascletis Pharma’s Acne Treatment Drug Application Accepted by China NMPA
6M ago
1672
Ascletis Pharma’s ASC30 Shows Promising Results in Obesity Treatment Study
Premium
Company Announcements
Ascletis Pharma’s ASC30 Shows Promising Results in Obesity Treatment Study
6M ago
1672

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >